Preliminary data from researchers in China suggest the NB.1.8.1 variant is not better at evading the immune system compared ...

An FDA committee on Thursday recommended that COVID-19 vaccines for the 2025-2026 respiratory virus season — which, for the ...

The variant, first detected in the U.S. in late March, has now been identified in arriving international travelers through ...

The US FDA may limit Covid-19 boosters to high-risk groups only, citing lack of efficacy in healthy individuals. Meanwhile, ...

The advisory committee meeting comes days after the FDA unveiled a new risk-based approval framework for COVID-19 vaccines.

The mRNA vaccines were developed using novel technology that was approved for the first time for public use during the COVID-19 pandemic.

The U.S. has detected the NB.1.8.1 COVID-19 variant, dominant in China, through airport screenings and health departments ...

On May 22, an FDA advisory committee unanimously recommended COVID-19 vaccine manufacturers target the JN.1 variant in their formulations.  The Vaccines and Related Biological Products Advisory ...

Despite the fact that vaccines against COVID have already undergone strict safety reviews and that people continue to die ...

Government advisers are meeting Thursday to decide if COVID-19 vaccines need updating to improve protection this fall and ...

The framework the new FDA leaders laid out on Tuesday raised small and big questions about the regulatory process, vaccine ...

The US Food and Drug Administration has ordered Pfizer and Moderna to expand their warning labels on COVID-19 vaccines.